An analysis of secondary outcomes in the SONIA trial showed that adverse events with CDK4/6 inhibitors were similar ...

and further support T-DXd as a valuable treatment option in this population,” they wrote in a scientific poster presented at the San Antonio Breast Cancer Symposium (SABCS) 2024. “We’re always worried ...